We propose that in addition to IHH and OPN, Runx2 mediates stimulation of osteoclast activity by up-regulating the expression of the osteoclastogenic cytokines IL-11 and GM-CSF in metastatic breast cancer cells (Figure 6C). Here, IL11 is linked to breast cancer.